Sareum Holdings plc (LON:SAR – Get Free Report) was up 16.5% during mid-day trading on Friday . The stock traded as high as GBX 30 ($0.38) and last traded at GBX 29.70 ($0.37). Approximately 924,968 shares changed hands during mid-day trading, a decline of 9% from the average daily volume of 1,018,599 shares. The stock had previously closed at GBX 25.50 ($0.32).
Sareum Stock Performance
The stock has a market capitalization of £30.98 million, a price-to-earnings ratio of -425.00 and a beta of -0.79. The firm has a fifty day moving average of GBX 21.38 and a 200-day moving average of GBX 42.92.
About Sareum
Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. It develops small molecule therapeutic drugs based on its Sareum Kinase Inhibitor Library drug discovery platform. The company's lead product is SDC-1801, a TYK2/JAK1 inhibitor that is in a Phase 1a clinical trials for the treatment of autoimmune diseases.
Further Reading
- Five stocks we like better than Sareum
- NYSE Stocks Give Investors a Variety of Quality Options
- Bounce Alert: 3 Large Caps With RSIs Too Good To Ignore
- Where to Find Earnings Call Transcripts
- Unity Software’s Mixed Q1, But Long-Term Outlook Remains Positive
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- JFrog Stock Gets Punished for Solid Results: Buy the Dip
Receive News & Ratings for Sareum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sareum and related companies with MarketBeat.com's FREE daily email newsletter.
